Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lipid nanoparticle drug delivery tech
Biotech
Xoma adds another struggling biotech to its buyout roster
After Generation Bio telegraphed major layoffs this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold.
Fraiser Kansteiner
Dec 16, 2025 11:00am
Korro lays off staff as lead drug disappoints, Novo pauses pact
Nov 13, 2025 7:20am
Generation Bio jettisons 90% of employees, including R&D org
Aug 13, 2025 5:00am
AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market
Jun 30, 2025 9:45am
NewLimit raises $130M to push liver mRNA med into clinic
May 6, 2025 11:00am
Tune Tx's $175M series B to fund epigenetic HBV therapy's trials
Jan 13, 2025 8:23am
